Your Heart Doesn't Wait for Menopause to Start Worrying

Episode Script

Thanks Toni. We've got a good one today.

It's Wednesday, which means Myth-Busting Monday is running a little late — and honestly, the material was worth waiting for. Three things on the table today, and all three push back on stories that get told about menopause a lot, including some that get told by people who should know better.

First up: a new paper in the NAMS journal — that's the journal of the North American Menopause Society — called "Challenging perception of inevitable health decline at menopause." The title is pretty much the thesis. The authors are making the case that the story we tell about menopause and health is wrong in a specific, damaging way.

The story goes like this: menopause happens, and then your body starts to fall apart. Bones thin. Heart risk goes up. Your brain gets foggy. Weight redistributes. And there's not much you can do about it because this is just what menopause does to women.

That story is not entirely made up — some of those things do happen, and the hormonal shift is real. But the framing of inevitability is what the paper pushes back on. And it matters, because how you frame something shapes what people do about it. If decline is inevitable, why bother? If it's manageable — if there are things that genuinely move the needle — the calculus changes completely.

The evidence the paper draws on is the same evidence that's been building for years: strength training protects bone density and metabolic health in ways that are genuinely significant. Good sleep hygiene matters more for cognition than most people realize. Protein intake — chronically underrated for women over 45 — plays a direct role in muscle preservation. And for many women, hormone therapy isn't a last resort; it's a first-line tool that works.

None of this is magic. None of it erases the transition. But "this is hard and there are real tools that help" is a completely different message than "your body is declining and there's nothing to be done." One of those messages leads women to engage with their health. The other leads them to disengage.

My read on this paper is that it's doing something important just by existing in a medical journal. Clinicians read NAMS. When a peer-reviewed paper says, explicitly, that the narrative of inevitable decline is misinformation — that carries weight in a way that a wellness blog post doesn't. It's the kind of framing shift that can eventually change what happens in a five-minute appointment.

The caveat I'd add is that "empowering" language can sometimes slide into minimizing real difficulty. Menopause is a significant physiological shift for many women, and some women have a genuinely hard time regardless of what they do. Saying decline isn't inevitable shouldn't become code for "if you're struggling, you're not trying hard enough." The paper doesn't seem to make that mistake, but it's worth naming.

Now — the Framingham Heart Study finding. This one is worth sitting with for a second.

Framingham is one of the most important long-running health studies ever conducted. It started in 1948 in Framingham, Massachusetts, and it's been tracking cardiovascular health across generations ever since. A lot of what we know about heart disease risk — cholesterol, blood pressure, smoking — came out of Framingham data. So when Framingham says something, it tends to be based on a very large amount of very carefully tracked information.

What the new analysis found is this: pulse pressure — which is the difference between your top and bottom blood pressure numbers — starts rising in women years before menopause, not after. Pulse pressure is a measure of how stiff your arteries are becoming. Higher pulse pressure generally means the arteries are losing flexibility, and that's a signal that cardiovascular stress is building.

The conventional assumption has been that heart risk for women ramps up after menopause, when estrogen levels drop. And estrogen does have protective effects on the cardiovascular system — that's real. But this Framingham finding suggests the process starts earlier, during perimenopause or even before it, which is a meaningfully different picture.

Why does that matter practically? Because if the window for intervention is during perimenopause — not after the final period — then waiting until menopause is confirmed to have a conversation about cardiovascular health means missing years of time when something could be done. Blood pressure monitoring, lifestyle adjustments, understanding your personal risk factors — these are conversations that should be happening earlier than they typically are.

This is a place where the medical system genuinely falls short. A woman in her mid-to-late forties who's still having periods, maybe irregularly, dealing with sleep disruption and mood changes — she's often not being screened or counseled with cardiovascular risk in mind. That five-minute appointment isn't asking about pulse pressure trends. It's often not asking about perimenopause at all.

The Framingham finding doesn't change what you do about cardiovascular health — the tools are the same: movement, blood pressure awareness, diet, not smoking, managing stress, getting your lipids checked. But it does argue strongly for starting those conversations earlier. Perimenopause is not a waiting room before the real menopause experience starts. Physiologically, it's already in motion.

The ashwagandha study. I want to be careful here because the supplement space is full of noise, and I don't want to add to it — but this study actually has something worth looking at.

Published in the same NAMS journal, this was a randomized, double-blind, placebo-controlled trial. That structure matters. It means women were randomly assigned to either take ashwagandha root extract or a placebo, and neither the women nor the researchers administering the trial knew who got what until the end. That design is specifically built to filter out the placebo effect and researcher bias. It's the standard you want to see when someone is making a claim about a supplement.

The trial ran for twelve weeks in postmenopausal women. The group taking ashwagandha reported significantly better sleep quality, improvement in menopausal symptoms, and changes in body composition compared to the placebo group. The researchers also noted a good safety profile — no significant adverse effects reported.

Ashwagandha is an adaptogen, a class of herbs that are thought to help the body manage stress. It's been used in Ayurvedic medicine for a long time, and it's had a surge of popularity in the wellness space — which is exactly why I'd normally be skeptical. Most of what gets sold as "stress-reducing" or "hormone-balancing" in that space is riding on testimonials and vague claims, not trial data.

This study is different in that it actually ran the right kind of test. That said, twelve weeks is not a long time, and one trial — even a good one — is not a green light to replace other treatments or assume the effects hold up over years. The study also can't tell us much about dose optimization, about which specific women are most likely to benefit, or about long-term safety. Those are open questions.

What I'd say is: this is a supplement that has earned a closer look. Not a supplement that has earned the "clinically proven to fix menopause" language you'll absolutely see on product packaging within the next six months, because that's how this works. A real study publishes, and the marketing machine picks it up and runs it somewhere the data doesn't actually go.

If you're curious about ashwagandha, the conversation to have is with your doctor — especially if you're on any medications, since adaptogens can interact with things like thyroid medications and sedatives. The kind of evidence your doctor would look at on a tool like OpenEvidence is building for this one, but it's not complete. That's an honest read of where things stand.

The thing that's genuinely useful about this study isn't just the ashwagandha finding. It's the reminder that "supplement" and "rigorously tested" are not mutually exclusive categories. Most supplements haven't been put through a proper trial. Some have. The job is to know the difference before spending money or, more importantly, making health decisions based on it.

TAGS:

• cardiovascular health
• perimenopause
• heart disease prevention
• ashwagandha
• sleep
• body composition
• myth-busting
• Framingham Heart Study
• supplements
• wellness misinformation
• NAMS

---

Sources curated automatically by the Hot Flasher pipeline.